PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells

Cellular Oncology

Volumn 32, Issue 1-2, 2010, Pages 11-27

  Kaarbø, Mari ^a   Mikkelsen, Øyvind Løveseter ^a   Malerød, Lene ^a   Qu, Su ^a   Lobert, Viola H ^a   Akgul, Gulcan ^a   Halvorsen, Thomas ^b   Mælandsmo, Gunhild M ^b   Saatcioglu, Fahri ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Androgen receptor; MTOR; PI3K pathway

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; TEMSIROLIMUS;

ARTICLE; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; CROSS LINKING; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO CULTURE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSACTIVATION; TRANSCRIPTION INITIATION; TRANSIENT TRANSFECTION; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 77749242462     PISSN: 15705870     EISSN: None     Source Type: Journal    
DOI: 10.3233/CLO-2009-0487     Document Type: Article

References (54)

1. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu and M.J. Thun, Cancer statistics, Cancer J. Clin. 57 (2007), 43-66.
2. G. Jenster, The role of the androgen receptor in the development and progression of prostate cancer, Semin. Oncol. 26 (1999), 407-421. (Pubitemid 29411449)
3. J.M. Kokontis and S. Liao, Molecular action of androgen in the normal and neoplastic prostate, Vitam. Horm. 55 (1999), 219-307.
4. C.D. Chen, D.S. Welsbie, C. Tran, S.H. Baek, R. Chen, R. Ves-sella, M.G. Rosenfeld and C.L. Sawyers, Molecular determinants of resistance to antiandrogen therapy, Nat. Med. 10 (2004), 33-39.
5. D.J. Lamb, N.L. Weigel and M. Marcelli, Androgen receptors and their biology, Vitam. Horm. 62 (2001), 199-230.
6. M. Kaarbo, T.I. Klokk and F. Saatcioglu, Androgen signaling and its interactions with other signaling pathways in prostate cancer, Bioessays 29 (2007), 1227-1238.
7. A. Bellacosa, C.C. Kumar, A. Di Cristofano and J.R. Testa, Activation of AKT kinases in cancer: implications for therapeutic targeting, Adv. Cancer Res. 94 (2005), 29-86.
8. J.A. Engelman, J. Luo and L.C. Cantley, The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism, Nat. Rev. Genet. 7 (2006), 606-619.
9. B.D. Manning and L.C. Cantley, AKT/PKB signaling: navigating downstream, Cell 129 (2007), 1261-1274.
10. L. Salmena, A. Carracedo and P.P. Pandolfi, Tenets of PTEN tumor suppression, Cell 133 (2008), 403-414.
11. D.A. Guertin and D.M. Sabatini, Defining the role of mTOR in cancer, Cancer Cell 12 (2007), 9-22.
12. M.S. Neshat, I.K. Mellinghoff, C. Tran, B. Stiles, G. Thomas, R. Petersen, P. Frost, J.J. Gibbons, H. Wu and C.L. Sawyers, Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR, Proc. Natl. Acad. Sci. USA 98 (2001), 10314-10319.
13. K. Podsypanina, R.T. Lee, C. Politis, I. Hennessy, A. Crane, J. Puc, M. Neshat, H. Wang, L. Yang, J. Gibbons, P. Frost, V. Dreisbach, J. Blenis, Z. Gaciong, P. Fisher, C. Sawyers, L. Hedrick-Ellenson and R. Parsons, An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten ± mice, Proc. Natl. Acad. Sci. USA 98 (2001), 10320-10325.
14. P.K. Majumder, P.G. Febbo, R. Bikoff, R. Berger, Q. Xue, L.M. McMahon, J. Manola, J. Brugarolas, T.J. McDonnell, T.R. Golub, M. Loda, H.A. Lane and W.R. Sellers, mTOR inhibition reverses Akt-dependent prostate intraepithelial neopla-sia through regulation of apoptotic and HIF-1-dependent pathways, Nat. Med. 10 (2004), 594-601.
15. P.K. Majumder and W.R. Sellers, Akt-regulated pathways in prostate cancer, Oncogene 24 (2005), 7465-7474.
16. L. Yang, H.K. Lin, S. Altuwaijri, S. Xie, L. Wang and C. Chang, APPL suppresses androgen receptor transactivation via potentiating Akt activity, J. Biol. Chem. 278 (2003), 16820-16827.
17. L. Yang, L. Wang, H.K. Lin, P.Y. Kan, S. Xie, M.Y. Tsai, P.H. Wang, Y.T. Chen and C. Chang, Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells, Biochem. Bioph. Res. Commun. 305 (2003), 462-469.
18. L. Yang, S. Xie, M.S. Jamaluddin, S. Altuwaijri, J. Ni, E. Kim, Y.T. Chen, Y.C. Hu, L. Wang, K.H. Chuang, C.T. Wu and C. Chang, Induction of androgen receptor expression by phos-phatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells, J. Biol. Chem. 280 (2005), 33558-33565.
19. H.K. Lin, S. Yeh, H.Y. Kang and C. Chang, Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor, Proc. Natl. Acad. Sci. USA 98 (2001), 7200-7205.
20. P. Li, S.V. Nicosia and W. Bai, Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells, J. Biol. Chem. 276 (2001), 20444-20450.
21. M. Sharma, W.W. Chuang and Z. Sun, Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation, J. Biol. Chem. 277 (2002), 30935-30941.
22. Q. Zhu, H. Youn, J. Tang, O. Tawfik, K. Dennis, P.F. Terranova, J. Du, P. Raynal, J.B. Thrasher and B. Li, Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers, Oncogene 27 (2008), 4569-4579.
23. L. Xin, M.A. Teitell, D.A. Lawson, A. Kwon, I.K. Mellinghoff and O.N. Witte, Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the andro-gen receptor, Proc. Natl. Acad. Sci. USA 103 (2006), 7789-7794.
24. T. Ikonen, J.J. Palvimo and O.A. Janne, Interaction between the amino-and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators, J. Biol. Chem. 272 (1997), 29821-29828.
25. P. Lefebvre, D.S. Berard, M.G. Cordingley and G.L. Hager, Two regions of the mouse mammary tumor virus long terminal repeat regulate the activity of its promoter in mammary cell lines, Mol. Cell. Biol. 11 (1991), 2529-2537.
26. K. Fronsdal, N. Engedal, T. Slagsvold and F. Saatcioglu, CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1, J. Biol. Chem. 273 (1998), 31853-31859.
27. T. Slagsvold, I. Kraus, T. Bentzen, J. Palvimo and F. Saatcioglu, Mutational analysis of the androgen receptor AF-2 (activation function 2) core domain reveals functional and mechanistic differences of conserved residues compared with other nuclear receptors, Mol. Endocrinol. 14 (2000), 1603-1617.
28. Z. Xi, T.I. Klokk, K. Korkmaz, P. Kurys, C. Elbi, B. Risberg, H. Danielsen, M. Loda and F. Saatcioglu, Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer, Cancer Res. 64 (2004), 2365-2370.
29. C.G. Korkmaz, K. Fronsdal, Y. Zhang, P.I. Lorenzo and F. Saat-cioglu, Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation-rescue of tran-scriptionally compromised mutants, J. Endocrinol. 182 (2004), 377-389.
30. M.A. Wainstein, F. He, D. Robinson, H.J. Kung, S. Schwartz, J.M. Giaconia, N.L. Edgehouse, T.P. Pretlow, D.R. Bodner, E.D. Kursh et al., CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma, Cancer Res. 54 (1994), 6049-6052.
31. C.G. Korkmaz, K.S. Korkmaz, P. Kurys, C. Elbi, L. Wang, T.I. Klokk, C. Hammarstrom, G. Troen, A. Svindland, G.L. Hager and F. Saatcioglu, Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancer, Oncogene 24 (2005), 4934-4945.
32. J.S. Horoszewicz, S.S. Leong, E. Kawinski, J.P. Karr, H. Rosenthal, T.M. Chu, E.A. Mirand and G.P. Murphy, LNCaP model of human prostatic carcinoma, Cancer Res. 43 (1983), 1809-1818.
33. Y. Xu, S.Y. Chen, K.N. Ross and S.P. Balk, Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cy-clin D proteins, Cancer Res. 66 (2006), 7783-7792.
34. B. Cinar, A. De Benedetti and M.R. Freeman, Post-transcriptional regulation of the androgen receptor by mammalian target of rapamycin, Cancer Res. 65 (2005), 2547-2553.
35. G. Deep, N.H. Oberlies, D.J. Kroll and R. Agarwal, Isosily-bin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway, Oncogene 27 (2008), 3986-3998.
36. J.A. Kemppainen, M.V. Lane, M. Sar and E.M. Wilson, Andro-gen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihor-mones, J. Biol. Chem. 267 (1992), 968-974.
37. D. Masiello, M.G. Mohi, N.C. McKnight, B. Smith, B.G. Neel, S.P. Balk and G.J. Bubley, Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer, Cancer Biol. Ther. 6 (2007), 195-201.
38. H.G. van der Poel, Mammalian target of rapamycin and 3- phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-beta1 in prostate cancer cells, J. Urologie 172 (2004), 1333-1337.
39. S. Mousses, U. Wagner, Y. Chen, J.W. Kim, L. Bubendorf, M. Bittner, T. Pretlow, A.G. Elkahloun, J.B. Trepel and O.P. Kallioniemi, Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling, Oncogene 20 (2001), 6718-6723.
40. E.C. Lee, P. Zhan, R. Schallhom, K. Packman and M. Ten-niswood, Antiandrogen-induced cell death in LNCaP human prostate cancer cells, Cell Death Differ. 10 (2003), 761-771.
41. P. Zhan, E.C. Lee, K. Packman and M. Tenniswood, Induction of invasive phenotype by Casodex in hormone-sensitive prostate cancer cells, J. Steroid Biochem. 83 (2002), 101-111.
42. S. Chan, M.E. Scheulen, S. Johnston, K. Mross, F. Cardoso, C.Dittrich, W. Eiermann, D. Hess, R. Morant, V. Semiglazov, M. Borner, M. Salzberg, V. Ostapenko, H.J. Illiger, D. Behringer, N. Bardy-Bouxin, J. Boni, S. Kong, M. Cincotta and L. Moore, Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer, J. Clin. Oncol. 23 (2005), 5314-5322.
43. S.M. Chang, P. Wen, T. Cloughesy, H. Greenberg, D. Schiff, C. Conrad, K. Fink, H.I. Robins, L. De Angelis, J. Raizer, K. Hess, K. Aldape, K.R. Lamborn, J. Kuhn, J. Dancey and M.D. Prados, Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme, Invest. New Drug. 23 (2005), 357-361.
44. C.L. Skotinicki J., A.L. Smith et al., Design, synthesis and biological evaluation of C-42 hydroxyesters of rapamycin: The identification of CCI-779, Clin. Cancer Res. 7 (2001), 3794S-3750S.
45. D.L. Lin, M.C. Whitney, Z. Yao and E.T. Keller, Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression, Clin. Cancer Res. 7 (2001), 1773-1781.
46. D. Accili and K.C. Arden, FoxOs at the crossroads of cellular metabolism, differentiation, and transformation, Cell 117 (2004) 421-426.
47. H.K. Lin, L. Wang, Y.C. Hu, S. Altuwaijri and C. Chang, Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase, Embo J. 21 (2002), 4037-4048.
48. E. Langley, Z.X. Zhou and E.M. Wilson, Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer, J. Biol. Chem. 270 (1995), 29983-29990.
49. P. Doesburg, C.W. Kuil, C.A. Berrevoets, K. Steketee, P.W. Faber, E. Mulder, A.O. Brinkmann and J. Trapman, Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor, Biochemistry-US 36 (1997), 1052-1064.
50. T.I. Klokk, P. Kurys, C. Elbi, A.K. Nagaich, A. Hendar-wanto, T. Slagsvold, C.Y. Chang, G.L. Hager and F. Saat-cioglu, Ligand-specific dynamics of the androgen receptor at its response element in living cells, Mol. Cell. Biol. 27 (2007), 1823-1843.
51. L. Wu, D.C. Birle and I.F. Tannock, Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts, Cancer Res. 65 (2005), 2825-2831.
52. Y. Wang, M. Mikhailova, S. Bose, C.X. Pan, R.W. deVere White and P.M. Ghosh, Regulation of androgen receptor tran-scriptional activity by rapamycin in prostate cancer cell proliferation and survival, Oncogene 27 (2008), 7106-7117.
53. L. Moro, A.A. Arbini, E. Marra and M. Greco, Mitochondrial DNA depletion reduces PARP-1 levels and promotes progression of the neoplastic phenotype in prostate carcinoma, Cell Oncol. 30 (2008), 307-322.
54. L. Moro, A.A. Arbini, J.L. Yao, P.A. di Sant'Agnese, E. Marra and M. Greco, Mitochondrial DNA depletion in prostate epithelial cells promotes anoikis resistance and invasion through activation of PI3K/Akt2, Cell Death Differ. 16 (2009), 571-583.